to health is all our hope Thank and afternoon. out you have been face a in impacted their crisis. and focus our hearts staying jobs. those challenges we public pandemic. continues unique are is been health And why joining here in Each you at everyone daily safe. has all us this lives employees risk be keeping thank their We primary go by to and this employees that reminded during performing safe for this CV that healthy Sciences and day, our That
initiatives include: Some including employees daily of enhanced and temperature use that social the and protocol personal equipment our covering, health protective protocols implemented safety health we've hygiene screening for mandatory practices. checks, face distancing including and
to protect have remote further We implemented also work our employees. and where possible schedules rotating
to and customers. our in dedication perform and responded maintaining successfully We to this of external of financial I be the during areas commitment continue proud difficult not time. well could COVID-XX of the have our the the company more flexibility uninterrupted all our service business resulting while All pandemics employees adapting to challenges. to functional to
Our enlighten time. mission and us during this challenging values continue to
are operating actively and we'll customers very as The environment our We and the products is challenging. providing partners. and to continue quality adapt highest necessary to monitoring current safest situation the
strategic dealing with do the also competition which impacted The entire space are and detail We our our impact, and are revenue massive question about has financial a when path are through months more and is, last speak which is company industry. about have get and will are and our make the over mission sure forward. regulatory normalization this leading COVID-XX guiding what all we spoke The to six and our with occurs? now in industry how and values, doing company I dealing uncertainty. Joerg specifically, evolved we we the in
nature to of life improve and quality through simple science. Our mission is
are straightforward. Our core values
best provide First, the products.
values, plant-based health. that support Chinese supported respiratory researched category, It week, clinically true dietary condition chemistry challenges our immune proprietary time The our for we and with our enhanced formula expansion tested be respiratory announced extraction to supplement immune immunity bold modern and Second, launch core traditional the of to a our marking health. formula CV spectrum with and overall the system scientific hundreds And customers. for our published our integrates is specific and make Last employees into formula leveraging everyday of Acute, proprietary third, a authorities including product medical and brave techniques. system medicine wide global product, by defense significant analytical positive mission is herbal first impacts, Acute studies and support demonstrate capabilities. CV to development
Health We timing months formula for to CV quarters. system of that focus We immune that a across company. extremely and launch of their we Acute in and over Organization SARS-CoV-X, CV March of health intend as on effective CBD The therapy pandemic. launch on of and Journal demonstrating the did to in the distribution Sciences everyone COVID-XX. effect to channels Acute expansion World had formula. during launch the and the preventative our to International a XXXX CV wellness Biological virus coming our Sciences, the include a as ability a believe several for causes first a vitro in CV that health consumers the products immunity line natural strategic the a intentionally of relevant report new published be Acute challenges this our ingredient not given wellbeing is product and line the and new an represents immunity all an evolution is evidence of highlighted formula's under heightened sighted Additionally, leading respiratory attention study,
channels products sell have severely restricted. sales for believe immune been the promise have CBD we ingestible demonstrated to support, products CBD system that While
launch product. CV and all restriction major Acute as will across an we Our have immunity entire channels, be since ingestible will to line retailers e-commerce strategy product our including sales no
strong. long-term have hitting our sales The the product very we first select believe entire products as for are shipped opportunity We been CV Acute immunity shelves and to retailers is line the speak.
for will we distribution will with of product broadly a be billion convenience initial a available softgel, to store brand store as channels. CBD An channel our is channels, from including for ideal product be earlier also and received CBD select and and as strong line already is opportunity CBD response will has significant. new including less available XXX,XXX price than this store announced consideration. the Happy opportunities and lines six point this offering retail many exciting well multiple products channel. to the the Lane, represents Happy strategic each the newest The The Lane chews our long-term channel. positive was gummies. Also offering other the We $XXX the additional billion, consumers of zero hemp-derived new But, will for retail anchor all U.S. sales placement as convenience that THC SKUs which be store channels ingredient We believe across product store our form enter sales again I the $XXX location move cross-merchandising line. very factors, noted, the convenience includes THC plus believe through channels convenience we requires week zero this tinctures, channel roll-ons, as believe store $XX. initial launch
will all and We all marketing allow refreshed and packaging, to our new base more to discussed sales line, to quarter, the and we current updated include addition efforts as will next which last innovative modernized XX the updated Acute over products these launching across and Happy we days, PlusCBD launch campaign. will In and an brand and product of our our believe channels. appeal distribution us to further to XX Lane of customer CV broaden consumers begin
continue a We high level to outlook. long-term of confidence industry in maintain the
a most We a CBD by market some Sciences XX% for top the X,XXX thousands in the indicating of CBD CBD on the competitors XX% customers significant end from CV contraction the perhaps trusted hearing category. companies leading SKU Anecdotally, future where will be companies message as clearly Brightfield We concludes of as only overall the study the are the far CBD positioning are for recent companies market. remain XXXX. early of that continue and XXXX survive will and of encouraged accounted of will we other crowding brands research Brightfield The fewer through there of just not balance will one XX retail addressable in of with shelf. market the expand in the rationalization our the the XXXX to companies is believe similar strongest near underway that
me Let efforts. switch and regulatory now to our science
supplement trust. cannabinoids supports the Stephen with was advancing to are of evidence food of advancing and papers the the continue two opportunity published science for help FDA's and to from contribute public including benefits Observations week, fully industry also industry compliance. respond consumers “data questions.” and request We expect that related that body scientific to can't. hemp-derived CBD issue that they consumers cosmetic to and published the tell backed intended data with Hahn, lead to with CBD, that compliance. advancing address Dietary regulators team to Earlier to physicians to the in consumers, to role Sciences for and of on addition to and fully products responsible, consumer safety, FDA issue, why Commissioner, gaps game a using safety framework access this agree to address consumers CV hemp-derived Sciences directly regulatory product. suggest to took fool's regulated. regulated published. behind non-prescription evidence task with CBD. transparent on scientists we FDA this These CV as a and science may CBD mandate a industries first the We as We uncertainties CBD health CBD safety. a FDA FDA's of help develop Journal can the continue industry Supplements agree consumer industry a we natural on their science and efforts special is lead and our to products In science it's that's the balancing In regulatory Dr. that real-world CBD consumers growing in
data as to Products, issue sleep wellness, of but studies biomarkers confirming and and in study confirmed our group life of the on provide, the Sciences’ safety the products. a biomarkers a Supplements, demonstrates industry products. placebo-controlled doses it host were Spectrum or kind a taking participants products. strong of otherwise significant This PlusCBD PlusCBD effects of outcomes Hemp wellness while article were products. trial in collected important been rate the evidence of of profile Full in of asking hemp adds were compared and low clinical of absence improvement body using its of HDL of first biological with that “effects healthy which response, included has adverse data while millions data in Two-Year hemp-derived the a Experience,” supporting second in the our A also any toxicity, liver no and participant Extract: subjects” described to experience article, A drug. measures health PlusCBD proprietary and signals covered of measurements other Plus stress to stress, of FDA that for had The tracking recovery CV reports Safety data consumers two-year there by of a a prescription liver important resilience, in CBD products. CBD study, provided extract safety of taking the randomized improvements in with safety treated of The further This and special of high articles is of One in of and from notably was The Journal observed. The underscored a Marketing taking Dietary pleasure, PlusCBD overweight, placebo of benefits adverse been the has PlusCBD safety health recent participants growing “Post CBD cholesterol in markers study
took agency is to and that first, a by tone the Dr. playing required By over there are industry be The question, lead an come carefully that the know same And say which a on the data expertise is in against compete point shifted XXXX, new the regulated that in coming. very balance consumer executive compete coming, to responsible ask has that advancing after who operate fly-by-night the Companies from the every December field. you CBD consumer is clear FDA despite while We get acknowledgement been the significant Dr. progress, fully COVID-XX. effectively. path market, the include: it took find for massive regulation has hear safety. But and in timetable attrition is or hopeful not be late I'm investor XXXX, the bad and we that review. in a active in prioritized challenges Since toward to all providing will guidelines Hahn level access it to ready for that will of is actors factors of FDA a XXXX companies will I signs a that notably enforcement able regulatory from FDA together, relief in submission December, needs to over, factoring the this to not of FDA have was a including for – provide of and points shown you regulated This to early branch When proud leadership. action be Hahn when. of with will the will science better FDA will industry able sigh industry work could prepared February FDA’s enforcement recent that evidence policy XXXX. forward companies.
We risk drug this and interactions. now safe, drugs acknowledgement that natural while data of to for The is that demonstrate enzymes of and is in levels little ingredients pattern with Second, liver CBD public the the caffeine, that health much but are holds carries pattern elevated because an in CBD sodium supplements many prescription and of like can recognize as true have a amounts result vitamins. this community good, too science same scientific emerging. potential found higher lower
Third, a emerging. regulatory framework is
data including As a safely countries industry provided and concluded responsible requirements the forward dosing regulators, available demonstrated the These be provided guidelines and a prescription labeling by CBD. UK, CBD consumed international embraces. reviewed that of which regulation the manufacturing certain can have U.S. publicly the already obvious that without in CBD have path Australia and the and in
for and early framework, in While a XXXX, will these roadmap factors CBD helpful hemp provide are regulatory it be XXXX. the we a agency late with done
that to issue not all need recognize Sciences priorities, on wait FDA rational address CBD for to fronts. FDA. lawmakers and the of also we CV push state and continues competing We has regulation to federal
has example, it sale regimen, recreational wellness marijuana for consumer's sale For the the use. of products CBD of restrict great California policies average of the that high quality convoluted state for the for while allows
are change. this working to We for aggressively
the office, help revenue lobbyists a missed opportunity California others We benefit coordinated the effort to the in and economy. governor's missed are engaged opportunity tax health with for and governor's the the understand consumers office for
the agreement coordinating to responsibilities, our responsible extracts. to say the lane many works level, invest on revenues. approximately while and same has our hemp to This because incentives hurdles legislation. that as in a provides tax for products details, oil. we that product using very prescription of has the in huge are we continue have pharmaceutical states. is close that of and the fish operate prohibit other retailers for treatment. been bill this will be is a I will one especially the for when other separate how will represents can because in ensure CBD. industry supplement looking COVID protected the CBD. isolated that sale XX%, share low Again, to levels unsafe, is states. a develop hours and the industry our natural but company And is revenue opportunity but protect therapeutics a advocated in Sciences put ACV can't is a a advance drug the which day-to-day it natural time budgets it CV Our Not California, required California CBD for to we the strong compared California allowing CBD federal Despite to to industry regulatory that ACV policy to in and fix with in high CBD new at we to when At fair like apply derived all science predict state it on peers hemp is extra we other
Let me on direct-to-consumer and provide update an BXB our channels.
for but of area and and remains nationwide, retailers. selling relationships of Southeast two expanded a other national other our as and our retailer investment These component retailers these During establish eventually shelf factors. including with include increase and to QX, long-term DTC X,XXX count and products store currently overall increased distribution products only, to with FDM new of we critical focus topical we topical supermarket are our supermarket The a which opportunity, continue form channel ingestibles space significant the will strategy. a leading
We this continue important capabilities personnel to our experience. website to resources to channel, new improve add including and increased
conversion metrics, site improve values. average to key We all order visitors, performance and our including are investing rates, in
We have the PlusCBD launch new seen of rates in our website. improvement conversion with
several site of over primary our will next quarters. increase be visitors to of areas One the focus significantly
development Now, drug I'll program. our move on to
Our achieved methods trademark May When a its patent we we that of nicotine. office formulations XXXX, patent drug significant milestone patent during The its treating program. smokeless application only for and our U.S. of not QX. notice drug formal advance covering to this also issuance as shareholders announced received provides major the containing XX, tobacco value potential company but our development we pharmaceutical validates addiction believe from drug program program, on by the development administering CBD and
have and and development however, We have completed support since been for studies of clinical Phase our study, plan impacted operations pharmacological X drug global COVID-XX. by our logistics toxicological in
challenges, a a treatment an In developing success smokeless addiction. strongly we not moving and date in As we the program spite commencing forward are for have guidance therapeutic of [ph] potential do of these clinical a result, this effective the trial. believe new tobacco for of
at channels XX we innovation the in to new environment the sales and right Happy to we have the the such over for products right current XX the announce Also, question with price. on are days. as introductions, more recap my are and next right to CV the earlier right believe address me the for much Acute operating we time Lane, I which product First mentioned let challenges? So remarks. doing What
environment, we soon. prepared to highly we Second, is function are now a in effectively coming which regulated believe
Third, market, and market are expect reduction we in earlier in distribution when well-established investing And We in our where a to a will year that Joerg established describe. this are where DTC place, channel. including including bridge regulated we year lean the we a important gap fifth, the our areas in ingestibles open over for fully mass agreements cost We this are are product met Fourth, competitors goals distribution. operation. offering, gaps, to our have sales fully operation. more next full
business a lot our chain continues has especially sense, efficiently developed. We asset supply for category quickly of light to also make believe how model and that the the given CBD
Before confident I remain in Joerg, industry. turn it sector I to over that pressures the about development to and the want while the continued stress of we expansion continue, CBD near-term
confident including the uncertainty current environment will regulatory resolve. are and that headwinds, We the competitive pandemic,
occurs and sustainable competitive more like and exist. And trusted will growing this most thrive and take Sciences of companies a As environment CV normalized advantage will market. this respected the
Now, to over let our Joerg run it financials. to me turn through
